EW: 2026 LAA Closure Expansion Will Support Upside Repricing

Analysts have nudged their fair value target for Edwards Lifesciences slightly lower to about $96.93, reflecting updated assumptions on discount rates, revenue growth, profit margins, and future P/E following a mix of recent price target cuts and raises across the Street.

Analyst Commentary

Recent research takes on Edwards Lifesciences point to a mixed but generally engaged stance from the Street, with both upgrades and target changes feeding into the updated fair value view.

Bullish Takeaways

Bullish analysts raising price targets into the US$90 to US$104 range point to support for Edwards' execution and long term growth framework, even as specific acquisition plans like JenaValve are taken off the table.
Updates to models following the blocked or cancelled JenaValve transaction, as well as management's new 2026 outlook, are framed by some as helpful for clarity on capital allocation and earnings power, which feeds into higher fair value estimates.
The move into left atrial appendage closure products and related surgical offerings is seen by some as an incremental growth driver, enough that competitors such as AtriCure are being reassessed, which underlines Edwards' competitive positioning in structural heart therapies.
Neutral ratings paired with slightly higher targets around the mid US$90s suggest that even less enthusiastic analysts still see room for fair value to sit above recent trading levels, assuming Edwards executes on its updated outlook.

Bearish Takeaways

Bearish analysts cutting price targets by amounts ranging from US$1 to US$13 are signaling concern around the risk reward skew, with valuation seen as less compelling after revisiting assumptions on discount rates, revenue growth and margins.
Target reductions following recent updates to earnings models highlight worries that execution on new product initiatives, including left atrial appendage offerings, could take longer or require more investment than previously built into forecasts.
JPMorgan and Goldman Sachs, along with other cautious voices, are using lower targets to flag that competition in structural heart and adjacent categories, as well as regulatory developments around deals, may weigh on how quickly Edwards can translate its pipeline into earnings.
The mix of upgrades and target cuts within a short time frame underscores that not all analysts are aligned on Edwards' medium term growth profile, which can justify a more conservative stance on valuation for investors focused on risk control.

What's in the News

New TRISCEND II data on the EVOQUE transcatheter tricuspid valve replacement system presented at ACC.26 show significant and sustained near elimination of tricuspid regurgitation, improvements in health status and quality of life, no added device related risk, and lower all cause mortality when accounting for patient crossover, extending earlier ESC 2025 findings and drawing on a body of evidence that includes more than 1,000 patients in the STS/ACC TVT Registry and approvals in the US and Europe (Key Developments).
For the first quarter of 2026, Edwards Lifesciences projects total sales between US$1.55b and US$1.63b, providing investors with a near term reference point for revenue expectations (Key Developments).
For full year 2026, the company issues guidance for a sales growth rate of 8% to 10% and EPS in a range of US$2.90 to US$3.05, outlining management's current financial framework for the year (Key Developments).
Between October 1, 2025 and December 31, 2025, Edwards repurchased 524,543 shares for US$39.8m, bringing total repurchases under the July 28, 2022 buyback to 47,329,908 shares, or 7.86%, at an aggregate cost of US$3,499.23m (Key Developments).

Valuation Changes

Fair value was trimmed slightly from about $97.12 to about $96.93 per share, reflecting modest tweaks to the core valuation inputs.
The discount rate was nudged up from roughly 7.72% to about 7.81%, indicating a small increase in the required return used in the model.
Revenue growth was adjusted marginally from about 9.87% to roughly 9.94%, leaving the long-term growth assumption broadly similar.
The net profit margin edged down from around 25.14% to about 25.09%, a very small change in expected profitability.
The future P/E was kept effectively stable, moving only slightly from about 33.78x to roughly 33.81x in the updated assumptions.

0 views

Key Takeaways

Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share.
Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.
Tariffs, competitive pressures, and strategic investments could impact Edwards Lifesciences' margins and revenue growth, requiring careful financial planning to achieve targets.

Catalysts

About Edwards Lifesciences

Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.What are the underlying business or industry changes driving this perspective?

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future.
The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
The recent approval of the Sapien M3 in Europe as the world's first transcatheter mitral valve replacement system signals Edwards' ability to address large, unmet patient needs, which could result in substantial revenue growth.
Edwards' ongoing investments in surgical innovation, such as the RESILIA tissue technology, are likely to expand access and adoption of its cardiovascular therapies globally, potentially improving net margins and bolstering revenue.
The company's plan to mitigate the financial impacts of announced tariffs and the JenaValve acquisition while maintaining its EPS guidance of $2.40 to $2.50 demonstrates an operational efficiency that could positively impact earnings.

Edwards Lifesciences Earnings and Revenue Growth

Edwards Lifesciences Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Edwards Lifesciences's revenue will grow by 9.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 17.5% today to 25.1% in 3 years time.
Analysts expect earnings to reach $2.0 billion (and earnings per share of $3.53) by about April 2029, up from $1.1 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $2.2 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.9x on those 2029 earnings, down from 43.0x today. This future PE is greater than the current PE for the US Medical Equipment industry at 26.3x.
Analysts expect the number of shares outstanding to decline by 0.99% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.81%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Edwards Lifesciences faces potential financial risks due to the impact of tariffs, which could affect the company's gross margins and net earnings, as they anticipate a $0.05 EPS impact from current tariffs in 2025, with greater impacts expected in 2026.
The acquisition of JenaValve may lead to an EPS dilution of $0.05 to $0.10, which could strain operating margins and necessitate careful planning to offset the acquisition costs in order to maintain earnings per share targets.
The competitive pressure in international markets, such as Japan, is exerting downward pressure on TAVR procedure growth, potentially impacting revenue growth and expansion efforts in these regions.
While Edwards anticipates expanding TAVR indications to asymptomatic patients, the regulatory and policy changes required for this may take longer than expected, delaying the projected revenues from this expanded patient base.
High levels of discretionary R&D spending, as well as necessary strategic investments to offset EPS impacts, indicate that operating expenses could rise, potentially impacting net profit margins if the expected growth in revenues does not materialize accordingly.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $96.93 for Edwards Lifesciences based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $84.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $8.1 billion, earnings will come to $2.0 billion, and it would be trading on a PE ratio of 33.9x, assuming you use a discount rate of 7.8%.
Given the current share price of $79.15, the analyst price target of $96.93 is 18.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Edwards Lifesciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead